<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455403</url>
  </required_header>
  <id_info>
    <org_study_id>201110238(3)</org_study_id>
    <secondary_id>P50HL083762</secondary_id>
    <nct_id>NCT00455403</nct_id>
  </id_info>
  <brief_title>Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)</brief_title>
  <acronym>ARCH-MS</acronym>
  <official_title>Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Singulex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome consists of a group of co-occuring conditions that increase an&#xD;
      individual's risk of developing heart disease, stroke, and diabetes. The purpose of this&#xD;
      study is to evaluate the long-term effectiveness of chloroquine, a protein-activation&#xD;
      medication, at reducing the progression of atherosclerosis in patients with the metabolic&#xD;
      syndrome.&#xD;
&#xD;
      Sub-study: Vascular endothelial growth factor(VEGF)and Cardiometabolic Risk, The purpose is&#xD;
      to determine if the association of VEGF with atherosclerosis indicates that it should be a&#xD;
      marker of the disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome is one of the most common disorders in industrialized countries. It&#xD;
      consists of abnormal serum lipids, glucose intolerance, elevated blood pressure, and central&#xD;
      obesity in the setting of insulin resistance. The syndrome substantially increases the risk&#xD;
      of developing diabetes and vascular disease, but there is no clear unifying approach to treat&#xD;
      this disorder. In animals, activation of the protein ataxia telangiectasia mutated (ATM)&#xD;
      using the antimalarial drug chloroquine improves features of metabolic syndrome and decreases&#xD;
      atherosclerosis, a build-up of fatty plaque within arteries. The purpose of this study is to&#xD;
      examine the effect of long-term treatment with low doses of chloroquine on atherosclerosis in&#xD;
      people with metabolic syndrome.&#xD;
&#xD;
      At a baseline study visit, participants will undergo an ultrasound of the neck to evaluate&#xD;
      carotid artery intima-media thickness (IMT) and MRI to evaluate plaque composition. In&#xD;
      addition, blood will be collected for laboratory testing and blood pressure will be measured.&#xD;
      Participants will then be randomly assigned to receive either placebo or chloroquine. Study&#xD;
      visits will occur every 3 months for 1 year. At each visit, blood pressure will be measured&#xD;
      and blood will be collected. At Months 6 and 12, a repeat ultrasound will be performed. At&#xD;
      month 12 a repeat carotid MRI is performed. Participants will attend one follow-up visit at&#xD;
      Month 24 and will undergo a final ultrasound.&#xD;
&#xD;
      Sub-Study: VEGF and Cardiometabolic Risk, (This is an observational, case-study of existing&#xD;
      baseline plasma and carotid intimal-medial thickness measurements) VEGF is also closely&#xD;
      linked to vascular disease. From cell culture and animal models it is known that VEGF is&#xD;
      increased in atherosclerotic lesions. It is controversial whether that relationship is&#xD;
      causative or reparative. Both pro- and anti-VEGF therapies have been proposed for&#xD;
      atherosclerosis. However, the association of VEGF with atherosclerosis indicates that it&#xD;
      should be a marker of the disorder, which is the hypothesis we wish to test. No previous&#xD;
      studies of circulating VEGF have been published.&#xD;
&#xD;
      Other markers may be related to vascular disease or VEGF in this dataset. Tumor necrosis&#xD;
      factor (TNF)-alpha results in increased expression of VEGF and may be correlated positively&#xD;
      with VEGF. By Erenna Technology testing, cardiac troponin I can be measured at levels much&#xD;
      lower than current clinical assays and is expected to be elevated in ischemia but not&#xD;
      necessarily in the stable vascular disease anticipated in our subjects. High sensitivity&#xD;
      C-reactive protein (hsCRP)has been proposed as a marker for vascular disease that merits drug&#xD;
      treatment in its own right and may also be correlated with VEGF and vascular disease.&#xD;
      However, currently the relationship between hsCRP and vascular disease is not completely&#xD;
      clear.&#xD;
&#xD;
      For this preliminary VEGF study observational data from the baseline only will be studied.&#xD;
      Baseline testing includes carotid artery intimal-medial thickness, carotid MRI, lipid panel,&#xD;
      complete blood count, comprehensive metabolic chemistry panel, Thyroid-stimulating hormone&#xD;
      (TSH) and glucose tolerance test with plasma insulin and glucose responses. Plasma collected&#xD;
      at baseline (approximately 1 ml) will be transferred to Singulex on dry ice. Samples will be&#xD;
      coded but will not contain patient identifiers. Erenna Technology assays will be done for&#xD;
      VEGF-A, cardiac troponin I,TNF-alpha, interleukin-6, interleukin-17A, and other cytokines at&#xD;
      Singulex. This method utilizes single-photon counting of visible light to improve assay&#xD;
      sensitivity. Separately, Washington University's Core Lab for Clinical Studies (CLCS) will&#xD;
      determine hsCRP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Carotid Intima-media Thickness From Baseline to Year 1</measure>
    <time_frame>Measured at baseline and year 1</time_frame>
    <description>A noninvasive predictor of cardiovascular events, Carotid artery intima-media thickness (CIMT) was measured from B-mode images by a single sonographer using standard approaches</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <condition>Overweight</condition>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Chloroquine Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 80 mg of chloroquine on a daily basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo comparator tablet on a daily basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24</description>
    <arm_group_label>Chloroquine Subjects</arm_group_label>
    <other_name>Arlen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24</description>
    <arm_group_label>Placebo Subjects</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of metabolic syndrome, as determined by at least three of the following five&#xD;
             criteria:&#xD;
&#xD;
               1. Elevated fasting triglyceride level greater than 150 mg/dL&#xD;
&#xD;
               2. Low HDL cholesterol levels: less than 50 mg/dL for women and less than 40 mg/dL&#xD;
                  for men&#xD;
&#xD;
               3. Hypertension (greater than or equal to 130/85 mm Hg and less than or equal to&#xD;
                  160/100 mm Hg) untreated; or hypertension controlled (less than or equal to&#xD;
                  150/90 mm Hg) on a stable medication regimen for 4 weeks prior to baseline visit.&#xD;
&#xD;
               4. Increased waist circumference: greater than 35 inches in women and greater than&#xD;
                  40 inches in men&#xD;
&#xD;
               5. Elevated fasting glucose level greater than or equal to 100 mg/dL and less than&#xD;
                  or equal to 126 mg/dL&#xD;
&#xD;
          -  Willing to use acceptable form of birth control&#xD;
&#xD;
          -  Subjects may be on a stable doses of a statin drug for at least 3 months&#xD;
&#xD;
          -  Subjects may be on a stable doses of L-thyroxine for at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior travel treatment with chloroquine or hydroxychloroquine as follows:&#xD;
&#xD;
               1. Any exposure in the past 2 years&#xD;
&#xD;
               2. More than 30 days of therapy if exposure was between 2 and 5 years ago&#xD;
&#xD;
               3. More than 90 days of therapy if exposure was between 5 and 10 years ago&#xD;
&#xD;
               4. More than 6 months of therapy if exposure was 10 to 20 years ago&#xD;
&#xD;
               5. More than 1 year of therapy if exposure was 20 to 30 years ago&#xD;
&#xD;
               6. No limit if last exposure was more than 30 years ago (e.g., during the Vietnam&#xD;
                  conflict)&#xD;
&#xD;
          -  Morbid obesity (body mass index [BMI] greater than 45)&#xD;
&#xD;
          -  Coronary artery disease or other vascular disease&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  Significant kidney disease (estimated glomerular filtration rate (eGFR)less than 60&#xD;
             mL/min/1.73 m2)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  History of psoriasis&#xD;
&#xD;
          -  Blood disorders, including anemia (i.e., hemoglobin levels less than 13 g/dL in men&#xD;
             and less than 12 g/dL in women)&#xD;
&#xD;
          -  Current malignancy or active treatment for recurrence prevention, example tamoxifen.&#xD;
             Cancer considered to be cured, either as a result of surgery or other treatment is not&#xD;
             exclusionary.&#xD;
&#xD;
          -  Asthma requiring daily beta agonist therapy or intermittent oral steroids is&#xD;
             exclusionary. Inhaled steroids are acceptable. Obstructive sleep apnea will be allowed&#xD;
             if Continuous Positive Airway Pressure (CPAP) or other therapy has been stable for 6&#xD;
             months. Other active respiratory diseases are excluded.&#xD;
&#xD;
          -  Liver disease, or liver function test results greater than twice the normal value&#xD;
&#xD;
          -  Active infection, including HIV&#xD;
&#xD;
          -  Serious illness requiring ongoing medical care or medication&#xD;
&#xD;
          -  Treatment with atypical anti-psychotic medication. Treatment with any other medication&#xD;
             for psychiatric illness, unless on a stable dose for 6 weeks prior to enrollment.&#xD;
             Patients with unstable psychiatric disorders are excluded per the decision of the&#xD;
             study MD regardless of medication history.&#xD;
&#xD;
          -  Receiving any of the following lipid lowering medications: niacin, fibrates, or fish&#xD;
             oils greater than 1 gram&#xD;
&#xD;
          -  Uncontrolled hypertension (blood pressure greater than or equal to 150/90) at baseline&#xD;
             visit.&#xD;
&#xD;
          -  Need for daily over the counter medications, or currently taking cimetidine or greater&#xD;
             than 1000 IU vitamin E daily and unwilling to reduce or discontinue the use of vitamin&#xD;
             E or discontinue cimetidine for the duration of the study. Patients taking greater&#xD;
             than 1000 IU of vitamin E should reduce the dose 30 days prior to randomization.&#xD;
&#xD;
          -  Pregnant, breastfeeding, or intending to become pregnant&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Retinal disease&#xD;
&#xD;
          -  Auditory disease or hearing loss; patients with total, irreversible hearing loss can&#xD;
             be enrolled&#xD;
&#xD;
          -  Participation in another clinical trial within past 30 days prior to screening and 60&#xD;
             days prior to randomization. Questionnaire or observational studies are not&#xD;
             exclusionary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clay F. Semenkovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://vfh.wustl.edu/</url>
    <description>click here for Washington University Research Participant Registry</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 30, 2007</study_first_submitted>
  <study_first_submitted_qc>March 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2007</study_first_posted>
  <results_first_submitted>October 6, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <disposition_first_submitted>March 17, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 17, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 20, 2020</disposition_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligibility included adults with at least 3 criteria of metabolic syndrome but who did not have diabetes. Subjects were studied in the setting of a single academic health center.</recruitment_details>
      <pre_assignment_details>241 participants screen failed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chloroquine Subjects</title>
          <description>Participants will receive 80 mg of chloroquine on a daily basis.&#xD;
Chloroquine: One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24</description>
        </group>
        <group group_id="P2">
          <title>Placebo Subjects</title>
          <description>Participants will receive a placebo comparator tablet on a daily basis.&#xD;
Placebo Comparator: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chloroquine Subjects</title>
          <description>Participants will receive 80 mg of chloroquine on a daily basis.&#xD;
Chloroquine: One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24</description>
        </group>
        <group group_id="B2">
          <title>Placebo Subjects</title>
          <description>Participants will receive a placebo comparator tablet on a daily basis.&#xD;
Placebo Comparator: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="12"/>
                    <measurement group_id="B2" value="55" spread="9"/>
                    <measurement group_id="B3" value="55" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Carotid Intima-media Thickness From Baseline to Year 1</title>
        <description>A noninvasive predictor of cardiovascular events, Carotid artery intima-media thickness (CIMT) was measured from B-mode images by a single sonographer using standard approaches</description>
        <time_frame>Measured at baseline and year 1</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine Subjects</title>
            <description>Participants will receive 80 mg of chloroquine on a daily basis.&#xD;
Chloroquine: One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24</description>
          </group>
          <group group_id="O2">
            <title>Placebo Subjects</title>
            <description>Participants will receive a placebo comparator tablet on a daily basis.&#xD;
Placebo Comparator: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Carotid Intima-media Thickness From Baseline to Year 1</title>
          <description>A noninvasive predictor of cardiovascular events, Carotid artery intima-media thickness (CIMT) was measured from B-mode images by a single sonographer using standard approaches</description>
          <population>Intent to treat</population>
          <units>millmeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.766" spread="0.17"/>
                    <measurement group_id="O2" value="0.765" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.758" spread="0.16"/>
                    <measurement group_id="O2" value="0.768" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.7279</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.010</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chloroquine Subjects</title>
          <description>Participants will receive 80 mg of chloroquine on a daily basis.&#xD;
Chloroquine: One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24</description>
        </group>
        <group group_id="E2">
          <title>Placebo Subjects</title>
          <description>Participants will receive a placebo comparator tablet on a daily basis.&#xD;
Placebo Comparator: Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>cutaneous staphylococcus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>positive PPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>transverse myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Right Knee Replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>carotid endarterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular</sub_title>
                <counts group_id="E1" events="51" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E2" events="57" subjects_affected="10" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergy/immunology</sub_title>
                <counts group_id="E1" events="51" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="42" subjects_affected="10" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="51" subjects_affected="39" subjects_at_risk="59"/>
                <counts group_id="E2" events="42" subjects_affected="37" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS</sub_title>
                <counts group_id="E1" events="51" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="57" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" events="51" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="57" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation of the study is that it may have been underpowered to detect a difference in CIMT. Sample size estimates at the time of initiation of these studies were based on reports showing that insulin sensitizers had effects on CIMT with groups of 31-57 subjects, but subsequent work indicated the need for larger sample sizes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Janet McGill, MD</name_or_title>
      <organization>Wash. Univ. School of Medicine</organization>
      <phone>314-362-8681</phone>
      <email>jmcgill@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

